First in human phase 1 study of DT2216, a selective BCL-xL degrader, in patients with relapsed/refractory solid malignancies. - Mahadevan, Daruka; Barve, Minal; Mahalingam, Devalingam; Parekh, Jay; Kurman, Michael; Strauss, James; Tremaine, Larry; Hromas, Robert; Sills, Joshua; McCulloch, John; Harkey, John; Suberg, Stacy; et al. (Journal of Hematology & Oncology, 2025)